Document Detail

Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases.
MedLine Citation:
PMID:  12438970     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Hemorrhagic cystitis (HC) is an important cause of morbidity in patients undergoing allogeneic stem-cell transplantation (SCT). Various causes have been identified, such as the use of high-dose cyclophosphamide or busulfan and the occurrence of acute graft-versus-host disease or viral infections (cytomegalovirus, adenovirus, polyomavirus). METHODS: The clinical course of four patients treated with factor XIII (FXIII) concentrate for severe HC after allogeneic SCT is described. RESULTS: Four patients were treated with one or two infusions of 50 IU/kg of FXIII concentrate. Only one patient showed a plasmatic FXIII decrease before treatment. Three of the four patients responded to this treatment, and HC completely resolved in two of them. No adverse event was observed. CONCLUSION: The use of FXIII concentrate can improve the major symptoms of HC in patients with decreased or normal FXIII plasma level after allogeneic SCT.
Karine Demesmay; Edgar Tissot; Claude-Eric Bulabois; Marie-Anne Bertrand; Evelyne Racadot; Marie-Christine Woronoff-Lemsi; Jean-Yves Cahn; Eric Deconinck
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Transplantation     Volume:  74     ISSN:  0041-1337     ISO Abbreviation:  Transplantation     Publication Date:  2002 Oct 
Date Detail:
Created Date:  2002-11-19     Completed Date:  2002-12-09     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1190-2     Citation Subset:  IM    
Department of Pharmacy, Besançon University Hospital, Boulevard Fleming, 25030 Besançon Cedex, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cystitis / complications*
Factor XIII / administration & dosage*
Hemorrhage / drug therapy*,  etiology*
Middle Aged
Stem Cell Transplantation / adverse effects*
Transplantation, Homologous
Reg. No./Substance:
9013-56-3/Factor XIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplant...
Next Document:  All chronic rejection failures of kidney transplants were preceded by the development of HLA antibod...